BI-3614
BI-3614 is a selective QPCTL/QPCT inhibitor with an IC50 of 4.0 nM for QPCTL and an IC50 of 2.5 nM for QPCT. BI-3614 can be used for research on Alzheimer's disease.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C18H15F3N6OS2
- Molecular Weight:452.48
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
IC50 & Target
[1]|
CYP3A4 16 μM (IC50) |
CYP2D6 >50 μM (IC50) |
CYP2C8 16 μM (IC50) |
CYP2C19 >50 μM (IC50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Raji | EC50 |
0.074 μM
|
Inhibition of SIRPα binding to CD47 on Raji cells using a Jurkat SIRPα reporter cell line.
Inhibition of SIRPα binding to CD47 on Raji cells using a Jurkat SIRPα reporter cell line.
|
5446662 |
In Vitro
BI-3614 has a Caco-2 A-B permeability of 3.3 μcm/s and an efflux ratio of 4.2[1].
BI-3614 shows <12 %QH in mouse hepatocytes[1].
BI-3614 exhibits 98.0% binding in mouse plasma[1].
BI-3614 inhibits CYP3A4 and CYP2C8 with an IC50 of 16 μM for both; the IC50 for CYP2D6 and CYP2C19 is >50 μM[1].
BI-3614 (10 μM) does not report off-target activity at a concentration of 10 μM across 38 kinases and 29 Bowes-44 panel targets[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 452.48
-
Formel C18H15F3N6OS2
-
SMILES
CC1=C(C2=C(C(F)(F)F)SC3=C2N=C(CSC4=NN=C(N)N4C)NC3=O)C=CC=C1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)